DexCom (NASDAQ:DXCM) EVP Sells $101,847.00 in Stock

DexCom, Inc. (NASDAQ:DXCM – Get Free Report) EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $59.91, for a total transaction of $101,847.00. Following the sale, the executive vice president owned 109,504 shares of the company’s stock, valued at $6,560,384.64. This represents a 1.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Jon Brown also recently made the following trade(s):

Get DexCom alerts:

• On Wednesday, April 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00.
• On Monday, March 16th, Michael Jon Brown sold 1,700 shares of DexCom stock. The stock was sold at an average price of $64.85, for a total transaction of $110,245.00.

DexCom Stock Up 0.6%

Shares of NASDAQ DXCM opened at $71.90 on Friday. The company has a 50 day simple moving average of $63.46 and a 200-day simple moving average of $65.94. The company has a market capitalization of $27.74 billion, a P/E ratio of 30.73, a P/E/G ratio of 1.18 and a beta of 1.40. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98.

DexCom (NASDAQ:DXCM – Get Free Report) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the firm earned $0.32 EPS. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, equities research analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current year.

Hedge Funds Weigh In On DexCom

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DXCM. Norges Bank purchased a new position in DexCom in the 4th quarter valued at approximately $483,356,000. AQR Capital Management LLC boosted its position in DexCom by 597.8% in the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after buying an additional 2,658,158 shares during the period. Holocene Advisors LP purchased a new position in DexCom in the 3rd quarter valued at approximately $163,964,000. CIBC Private Wealth Group LLC boosted its position in DexCom by 374.3% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock valued at $195,666,000 after buying an additional 2,294,709 shares during the period. Finally, Employees Provident Fund Board purchased a new position in DexCom in the 4th quarter valued at approximately $145,352,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the subject of several research reports. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Robert W. Baird set a $80.00 target price on shares of DexCom in a report on Friday, May 1st. BTIG Research reiterated a “buy” rating and issued a $85.00 target price on shares of DexCom in a report on Monday, March 9th. Wells Fargo & Company dropped their target price on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Finally, William Blair upgraded shares of DexCom to a “strong-buy” rating in a report on Friday, May 15th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $82.21.

Check Out Our Latest Research Report on DexCom

DexCom Company Profile

(Get Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Featured Articles

• Five stocks we like better than DexCom
• Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
• As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
• Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
• The Silver Lining of Last Week’s Hims & Hers Earnings Miss

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.